Type 2 Diabetes Mellitus (T2DM)
Conditions
Brief summary
This study is a first-in-human randomized, double-blind (Investigator and subject), placebo controlled single ascending dose study that will enroll approximately 40 (6 active/2 placebo per dose group) adult male and female subjects with Type 2 Diabetes Mellitus (T2DM).
Interventions
DRUGPE0139 Injection
DRUGPlacebo
Sponsors
PhaseBio Pharmaceuticals Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Willing and able to sign a written informed consent and follow all study-related procedures; * Male and female subjects at least 18 years of age; * Male subjects and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their dose of study drug; * Body mass index ≤45 kg/m2; * Diagnosed with T2DM and who is currently taking a stable daily dose of a basal insulin (Lantus) plus at least one oral antihyperglycemic agent at a stable dose for 3 months prior to screening.
Exclusion criteria
* Currently taking or have taken within 3 months prior to screening an approved or investigational GLP-1 analogue/agonist (e.g., Victoza®) or pramlintide; * Currently taking or have routinely taken, within 3 months prior to screening , a short-acting insulin; * Currently taking or have taken, within 3 months prior to screening, a long acting insulin other than Lantus®; * Known allergy to, or serious adverse effect caused by an approved, or investigational insulin product or any of its components; * Currently taking any of the following medications: thiazide or furosemide diuretics, beta-blockers, estrogens or other hormonal replacement therapy, or other chronic medications with known adverse effects on glucose tolerance levels unless the subject has been on stable doses of such agents for at least 2 months prior to screening and have no planned changes during the study period; * History of recurrent severe hypoglycemia (more than 2 episodes within the last 6 months prior to randomization or hypoglycemic unawareness; * Malignant disease defined as 1) any history of malignant melanoma or breast cancer and/or 2) history of other types of cancer within the last 5 years prior to screening; * Unstable cardiovascular disease defined as one or more of the following: History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to screening; History of or currently have New York Heart Association Class III-IV heart failure prior to screening; Uncontrolled/sustained hypertension; History or evidence of long QT syndrome or mean triplicate 12-lead electrocardiogram demonstrating QT interval; * Clinically significant renal and/or hepatic dysfunction; * Absolute requirement for corticosteroids or have received systemic steroids within 3 months prior to Randomization (V5, Day -1). Note: Use of inhaled or topical corticosteroids will be permitted; * Pregnant or lactating female subjects; * Known history of or active alcohol abuse or use of illicit drugs within 1 year prior to screening; * Positive screening for human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C virus antibodies at V1; * Participating in any other study and have received any other investigational medication or device within 30 days prior to Visit 1. * Other medical or psychiatric condition which, in the opinion of the Investigator, would place the subject at increased risk.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in ECGs from baseline (Day -1) | ECG Days 2 and 28 | Safety will be evaluated by analyses of the change from baseline in 12-lead ECG. |
| Incidence and severity of immunogenicity | Immunogenicity Days 0, 7, 14 and 28 | Safety will be evaluated by the incidence and severity of immunogenicity. |
| Incidence and severity of adverse events including hypoglycemia | As reported between Days -10 to 28 | Safety will be evaluated by the incidence and severity of adverse events including hypoglycemia. |
| Change in Vital Signs from baseline (Day 0 Pre-dose) | Vital signs Day 0, 1, 2, 3, 4, 5, 6, 7, 14 and 28 | Safety will be evaluated by analyses of the change from baseline in vital signs. |
| Change in Safety Labs from baseline (Pre-dose) | Safety Labs Days 0, 7 and 28 | Safety will be evaluated by analyses of the safety laboratory parameters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacodynamic Response | FPG Day -10, -4, 0, 1, 2, 3, 4, 5, 6, 7, and 28; 4-pt Glucose and CGM - Day -10 to -7, -6, -5, and -4 to 7 | To assess the pharmacodynamic response (time action profile) of various single doses of PE0139. Assessments include Fasting plasma glucose (FPG), 4-point serial glucose monitoring and glucose assessed by continuous glucose monitoring (CGM). |
| Pharmacokinetic Profile | Day 0, 1, 2, 3, 4, 5, 6, and 7 | Pharmacokinetic parameters include: Area under the concentration curve from time 0 to infinity (AUC(0-inf)), Area under the concentration curve to the final sample with a concentration greater than or equal to Limit of Quantitation (LOQ) (AUC(0-t)), Time to maximum concentration (Tmax), Maximum serum concentration (Cmax), Elimination rate constant (Lambda-z), Elimination half-life (t1/2), Clearance uncorrected for bioavailability (CL/F), Distribution uncorrected for bioavailability (Vz/F) |
Countries
United States
Outcome results
None listed